Abstract
Background
The main mechanism of action of propafenone (antiarrhythmic drug) involves the inhibition of the fast inward sodium current during phase 0 of the action potential. Sodium channel-blocking activity is also characteristic for some antiepileptic drugs. Therefore, it could be assumed that propafenone may also affect seizures. In the present study, we evaluated the effect of propafenone on the protective effect of oxcarbazepine, lamotrigine, topiramate and pregabalin against the maximal electroshock-induced seizures in mice.
Methods
Anticonvulsant activity of propafenone was assessed with the maximal electroshock seizure threshold (MEST) test. Influence of propafenone on the anticonvulsant activity of antiepileptic drugs was estimated in the mouse maximal electroshock model (MES). Drug-related adverse effects were determined in the chimney test (motor coordination) and passive-avoidance task (long-term memory). Brain concentrations of antiepileptics were assessed by fluorescence polarization immunoassay.
Results
Propafenone at doses 60–90 mg/kg significantly increased the threshold of seizures, in turn at doses 5–50 mg/kg did not affect this parameter. Administration of propafenone at the subthreshold dose of 50 mg/kg increased antielectroshock activity of oxcarbazepine, topiramate and pregabalin, but not that of lamotrigine. As regards adverse effects, propafenone alone and in combination with antiepileptic drugs did not significantly impair motor coordination or long-term memory in mice. Propafenone (50 mg/kg) significantly increased the brain level of pregabalin. Brain concentrations of topiramate and oxcarbazepine were not affected.
Conclusion
Our findings show that propafenone has own anticonvulsant action and enhances efficacy of oxcarbazepine, topiramate and pregabalin, but not that of lamotrigine, at least in experimental condition.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wolber T., Namdar M, Duru F. Heart obeys the brain: seizure ceases cardiac rhythm. PACE 2010;33(8):e72–5.
Benarroch EE. HCN channels: function and clinical implications. Neurology 2013;80(3):304–10.
Roubille F, Tardif JC. New therapeutic targets in cardiology, heart failure and arrhythmia: HCN channels. Circulation 2013;127(19):1986–96.
Panayiotopoulos CP. The new ILAE report on terminology and concepts for the organization of epilepsies: critical review and contribution. Epilepsia 2012;53(3):399–404.
García-Cosío F, Pastor Fuentes A, Núñez Angulo A. Arrhythmias (IV). Clinical approach to atrial tachycardia and atrial flutter from an understanding of the mechanisms. Electrophysiology based on anatomy. Rev Esp Cardiol (Engl Ed) 2012;65(4):363–75.
Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol 2010;588:1849–59.
Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. Sci Transl Med 2009;1(2):1–19.
Lathers CM, Schraeder PL, Weiner FL. Synchronization of cardiac autonomic neural discharge with epileptogenic activity: the lockstep phenomenon. Electroencephalogr Clin Neurophysiol 1987;67(3):247–59.
Scorza FA, Arida RM, Cysneiros RM, Terra VC, Sonoda EY, de Albuquerque M, et al. The brain-heart connection: implications for understanding sudden unexpected death in epilepsy. Cardiol J 2009;16(5):394–9.
Jehi L, Najm IM. Sudden unexpected death in epilepsy: impact, mechanisms, and prevention. Cleve Clin J Med 2008;75(2):66–70.
Tolstykh GP, Cavazos JE. Potential mechanisms of sudden unexpected death in epilepsy. Epilepsy Behav 2013;26(3):410–4.
Velagapudi P, Turagam M, Laurence T, Kocheril A. Cardiac arrhythmias and sudden unexpected death in epilepsy (SUDEP). PACE 2012;35(3):363–70.
Scholz H. Classification and mechanism of action of antiarrhythmic drugs. Fundam Clin Pharmacol 1994;8(5):385–90.
Lipkind GM, Fozzard HA. Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol 2010;78(4):631–8.
Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9(4):413–24.
Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 2002;7(7):726–33.
Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 1998;46(4):307–19.
Czapinski P, Błaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5(1):3–14.
Banach M, Piskorska B, Borowicz-Reutt KK. Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model. Pharmacol Rep 2016;68(3):555–60.
Castel-Branco MM, Alves GL, Figueiredo, Falcão AC, Caramona MM. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol 2009;31(2):101–6.
Zagaja M, Andres-Mach M, Patrzylas P, Pyrka D, Szpringer M, Florek-Łuszczki M, et al. Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice. Fitoterapia 2016;115:86–91.
Łuszczki JJ, Trojnar MK, Trojnar MP, Kimber-Trojnar Z, Szostakiewicz B, Zadrożniak A, et al. Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 2007;59(6):672–82.
Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96(2):99–113.
Boissier JR, Tardy J, Diverres JC. Une nouvelle methode simple pour explorer l’action tranquilisante: le test de la cheminee. Med Exp (Basel) 1960;3:81–4.
D’Orazio JL, Curtis JA. Overdose of propafenone surreptitiously sold as Percocet. J Emerg Med 2011;41(2):172–5.
Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015;3:CD005049.
Chimienti M, Cullen Jr. MT, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 12 1995;16:1943–51.
Ito N, Tashiro T, Morishige N, Nishimi M, Hayashida Y, Takeuchi K, et al. Efficacy of propafenone hydrochloride in preventing postoperative atrial fibrillation after coronary artery bypass grafting. Heart Surg Forum 2010;13(4):E223–7.
Kowey PR, Yannicelli D, Amsterdam E. COPPA-II Investigators: effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004;94(5):663–5.
Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, et al. ERAFT Investigators: efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002;90(12):1300–6.
Zehender M, Hohnloser S, Geibel A, Furtwängler A, Olschewski M, Meinertz T, et al. Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. Br Heart J 1992;67(6):491–7.
Gulizia M, Mangiameli S, Orazi S, Chiarandà G, Piccione G, Di Giovanni N, et al. PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: a Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 2008;155(1):100–7.
Fernández J, Lligoña L, Puigdemont A, Guitart R, Riu JL, Arboix M. Tissue distribution of propafenone in the rat after intravenous administration. Eur J Drug Metab Pharmacokinet 1991;16(1):23–7.
von Philipsborn G, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, Müller CD, et al. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 1984;34(11):1489–97.
Borowicz-Reutt KK, Banach M, Piskorska B. Mexiletine and its interactions with classical antiepileptic drugs: an isobolographic analysis. Neurochem Res 2016;41(5):1185–91.
Alexander GJ, Kopeloff LM, Alexander RB, Chatterjie N. Mexiletine: biphasic action on convulsive seizures in rodents. Neurobehav Toxicol Teratol 1986;8(3):231–5.
Akkan AG, Yillar DO, Eskazan E, Akcasu A, Ozüner Z. The effect of propranolol on maximal electroshock seizures in mice. Int J Clin Pharmacol Ther Toxicol 1989;27(5):255–7.
De Sarro G, Di Paola ED, Ferreri G, De Sarro A, Fischer W. Influence of some beta-adrenoceptor antagonists on the anticonvulsant potency of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Eur J Pharmacol 2002;442(3):205–13.
Fischer W. Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers. Seizure 2002;11(5):285–302.
Khanna N, Ray A, Alkondon M, Sen P. Effect of beta-adrenoceptor antagonist and some related drugs on maximal electroshock seizures in mice. Indian J Exp Biol 1989;27(2):128–30.
Nakamura T, Oda Y, Takahashi R, Tanaka K, Hase I, Asada A. Propranolol increases the threshold for lidocaine-induced convulsions in awake rats: a direct effect on the brain. Anesth Analg 2008;106(5):1450–5.
Goel R, Goel A, Kumar Y. Anticonvulsant activity with neuropharmacological benefits of nebivolol in mice. Pharmacology online 2011;1:406–13.
Lathers CM, Stauffer AZ, Tumer N, Kraras CM, Goldman BD. Antiarrhythmic actions of Anticonvulsant the beta blocking agent timolol. Epilepsy Res 1989;4(1):42–54.
De Sarro G, De Sarro A, Federico F, Meldrum BS. Anticonvulsant properties of some calcium antagonists on sound-induced seizures in genetically epilepsy prone rats. Gen Pharmacol 1990;21(5):769–78.
Kułak W, Sobaniec W, Wojtal K, Czuczwar SJ. Calcium modulation in epilepsy. Pol J Pharmacol 2004;56(1):29–41.
Vezzani A, Wu HQ, Stasi MA, Angelico P, Samanin R. Effect of various calcium channel blockers on three different models of limbic seizures in rats. Neuropharmacology 1988;27(5):451–8.
Wurpel JN, Iyer SN. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 1994;35(2):443–9.
El-Azab MF, Moustafa YM. Influence of calcium channel blockers on anticonvulsant and antinociceptive activities of valproic acid in pentylenetetrazolekindled mice. Pharmacol Rep 2012;64(2):305–14.
Jagiełło-Wójtowicz E, Czuczwar SJ, Chodkowska A, Szponar J, Kleinrok Z. Influence of calcium channel blockers on pentylenetetrazole and electro-shock-induced convulsions in mice. Pol J Pharmacol 1991;43(2):95–101.
Mori K, Ito H, Toda Y, Hashimoto T, Miyazaki M, Saijo T, et al. Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion. Epilepsia 2004;45(10):1287–90.
de Oliveira GG, Borges MA. Propranolol action in chronically unstable generalized epilepsy. Am J Ther 1994;1(1):38–41.
Enoki H, Hata H, Ohmori I, Maniwa S, Ohta H, Kobayashi K. Clinical applications and the effect of mexiletine on refractory epilepsies (Japanese). No To Hattatsu 2000;32(1):29–34.
Miyamoto A, Takahashi S, Oki J. A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox-Gastaut syndrome (Japanese). No To Hattatsu 1999;31(5):459–64.
Nakazawa M, Okumura A, Niijima S, Yamashita S, Shimono K, Hirose S, et al. Oral mexiletine for lidocaine-responsive neonatal epilepsy. Brain Dev 2013;35(7):667–9.
Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46(6):967–9.
Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 2010;17(4):565–8.
Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004;38(10):1631–4.
Luchowska E, Luchowski P, Wielosz M, Kleinrok Z, Czuczwar SJ, Urbańska EM. Propranolol and metoprolol enhance the anticonvulsant action of valproate and diazepam against maximal electroshock. Pharmacol Biochem Behav 2001;71(1–2):223–31.
Goel R, Goel A, Manocha A, Pillai KK, Srivastava RS. Influence of nebivolol on anticonvulsant effect of lamotrigine. Indian J Pharmacol 2009;41(1):41–6.
Czuczwar SJ, Chodkowska A, Kleinrok Z, Małek U, Jagiełło-Wójtowicz E. Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur J Pharmacol 1990;176(1):75–83.
Łuszczki JJ, Trojnar MK, Trojnar MP, Kimber-Trojnar Z, Szostakiewicz B, Zadrozniak A, et al. Effects of amlodipine, diltiazem, and verapamil on the anticonvulsant action of topiramate against maximal electroshock-induced seizures in mice. Can J Physiol Pharmacol 2008;86(3):113–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borowicz-Reutt, K.K., Popławska, M., Banach, M. et al. Influence of propafenone on the anticonvulsant activity of various novel antiepileptic drugs in the mouse maximal electroshock model. Pharmacol. Rep 70, 481–487 (2018). https://doi.org/10.1016/j.pharep.2017.11.014
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2017.11.014